Novozymes, a platform focused on human health applications within oral and gut health, agreed to acquire Microbiome Labs, a firm offering proprietary probiotic and microbiome solutions, for $125m. “Within a few years, Microbiome Labs has built a solid market position and become a key opinion leader on the microbiome in the consumer health industry, and I am very happy to welcome Microbiome Labs to the Novozymes family. With its solid product portfolio and position with health practitioners, the company is a natural fit and matches our strategy of winning through scientifically proven solutions with specific health benefits,” Ester Baiget, Novozymes President and CEO.